COMMUNIQUÉS West-GlobeNewswire

NEOVACS : Le Comité Indépendant de Surveillance des Données et de la Tolérance confirme le bon déroulement de l'essai clinique de phase IIb dans le lupus
11/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Le Comité Indépendant de Surveillance des Données et de la Tolérance (iDSMB) confirme le bon déroulement de l'essai clinique de phase IIb dans le lupus avec l'IFNalpha [...]
Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
11/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus Third positive data review by IDSMB follows completion of patient [...]
Sanofi to acquire Protein Sciences
11/07/2017
Sanofi to acquire Protein Sciences - Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio - Paris, France - July 11, 2017 - Sanofi announced today it will acquire Protein Sciences, a [...]
Sanofi sur le point d'acquérir Protein Sciences
11/07/2017
Sanofi sur le point d'acquérir Protein Sciences - Cette acquisition permettra à Sanofi Pasteur d'enrichir son portefeuille d'un vaccin antigrippal recombinant - Paris, France - Le 11 juillet 2017 - Sanofi annonce [...]
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
10/07/2017
Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Months of Follow-Up Second-dose Cohort Demonstrates Dose Response Up to One Year, with 84% Reduction in Spontaneous Bleeds and All [...]
Ossur Hf : Transactions in relation to share buyback program
10/07/2017
Announcement from Össur hf. No. 48/2017 Reykjavík, 10 July 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Sanofi : Disclosure of trading in own shares
10/07/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
10/07/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
GENFIT : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC
10/07/2017
GENFIT : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC Lille (France), Cambridge (Massachusetts, Etats-Unis), le 10 juillet 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique [...]
GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC
10/07/2017
GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC Lille (France), Cambridge (Massachusetts, United States), July 10, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the [...]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
10/07/2017
Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) [...]
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
10/07/2017
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors - With up [...]
Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients...
10/07/2017
Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients atteints d'hémophilie A [...]
AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
10/07/2017
Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates on the advancement of [...]
ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation
10/07/2017
Updated corporate overview available on ProMIS website TORONTO and CAMBRIDGE, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of [...]
Virbac : Déclaration d'actions et de droits de vote au 30 Juin 2017
10/07/2017
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights as of June 2017, 30.
10/07/2017
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
10/07/2017
Oslo (Norway), 10 July 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]
ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement
10/07/2017
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy [...]

Pages